Clinical Trial Update: Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008) [Phase 3]

View source ↗

Summary

This update reports longer-term results for AR101 in participants who previously enrolled in ARC008, providing insights from a Phase 3 peanut allergy study. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peanut Allergy

Drugs mentioned

• AR101 (peanut oral immunotherapy)

Snippet

Sponsor: Aimmune Therapeutics, Inc. | Conditions: Peanut Allergy | Phase 3 | Status: COMPLETED | Results posted: 2024-12-19